Author

Hervé Curé

Observed names: Curé, Hervé, H CURE, H Cure, Herve Cure, Herve Curé, Hervé Cure, Hervé Curé, Hervé Cure, Hervé D. Curé, Herv� Cur�

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Inserm, Université Clermont Auvergne, Queen Elizabeth Hospital Birmingham, Centre Hospitalier Universitaire de Grenoble, Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage, Hospices Civils de Lyon, Centre Léon Bérard, Hôpital Notre-Dame, Centre Eugène Marquis, Dana-Farber Cancer Institute, Centre François Baclesse, Hôpital Edouard Herriot, Centre Jean Perrin, European Organisation for Research and Treatment of Cancer, Institut Claudius Regaud, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Oscar Lambret, Institut Bergonié, Centre Hospitalier de l’Université de Montréal, Institut Paoli-Calmettes, Institut Jean Godinot, Institut pour l'avancée des biosciences, Instituto Nazionale Tumori Regina Elena, Université de Clermont I, University of Colorado Anschutz, Université de Montréal, Université de Reims Champagne-Ardenne, KU Leuven

OpenAlex ID: A5103548051

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

2012 · Thomas Bachelot, Gilles Romieu, et al. · The Lancet Oncology · 743

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

2014 · Pierre Soubeyran, Carine Bellera, et al. · PLoS ONE · 622

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

2007 · Henri Roché, Louise Yelle, et al. · Journal of Clinical Oncology · 221

Low grade supratentorial astrocytomas. Management and prognostic factors

1994 · Pierre Janny, Hervé Cure, et al. · Cancer · 182

PDF

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

2013 · Geraldine Gebhart, Cristina Gámez, et al. · Journal of Nuclear Medicine · 162

PDF

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

2013 · Stéphanie Cochaud, Jérôme Giustiniani, et al. · Scientific Reports · 158

PDF

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

2016 · Hakim Mahammedi, Eloise Planchat, et al. · Oncology · 143

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

2013 · Ignace B. Vergote, Antonio Jimeno, et al. · Journal of Clinical Oncology · 121

PDF

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

2005 · Sophie Catherine Abrial, Frédérique Penault-Llorca, et al. · Breast Cancer Research and Treatment · 109

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

2007 · Olivier Tacca, Frédérique Penault-Llorca, et al. · The Oncologist · 107

Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial

2006 · Jean-Pierre Droz, Andrew Kramar, et al. · European Urology · 84

Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy

2002 · Hervé Curé, Sophie Amat, et al. · Breast Cancer Research and Treatment · 74

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

2015 · Anne de la Rochefordiere, Maud Kamal, et al. · Clinical Cancer Research · 58

Positron Emission Tomography in oncology: Present and future of PET and PET/CT

2008 · Dimitri Papathanassiou, Claire Bruna-Muraille, et al. · Critical Reviews in Oncology/Hematology · 58

Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis

1993 · Jocelyne Attia-Sobol, Jean-Pierre Ferrière, et al. · European Journal of Cancer · 58

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol

2004 · Jean-Pierre Lotz, Hervé Curé, et al. · European Journal of Cancer · 51

Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer

2006 · Philippe Chollet, Catherine Abrial, et al. · Clinical Breast Cancer · 49

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

2007 · Philippe A. Cassier, Sylvie Chabaud, et al. · Breast Cancer Research and Treatment · 46

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

2013 · Hatem A. Azim, Francoise Rothé, et al. · The Breast · 39

PDF

Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study

2016 · Jean-Claude Karp, Carole Sanchez, et al. · Homeopathy · 35

IL-17E synergizes with EGF and confersin vitroresistance to EGFR-targeted therapies in TNBC cells

2016 · Yacine Merrouche, Joseph Fabre, et al. · Oncotarget · 31

PDF

Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy

2006 · Aurélie Cabrespine, Laurent Guy, et al. · The Journal of Urology · 31

Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer

2006 · Aurélie Cabrespine, Laurent Guy, et al. · Urology · 31

Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer.

2003 · Virginie Chevalier, Marie-Christine Mormont, et al. · PubMed · 29

Detection of epstein‐barr viral genomes in lymph nodes of Hodgkin's disease patients

1990 · Yves‐Jean Bignon, Dominique Bernard, et al. · Molecular Carcinogenesis · 28

Works count: 80

Citation count: 3,606

H-index: 26

I10-index: 38